<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   Vital Therapies, Inc.
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
        139993690
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       163211
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       2
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   Vital Therapies develops therapies that prevent liver failure. The company's product candidate, the ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body and is designed to initiate gradual liver regeneration or to stabilize the patient until a transplant can be conducted. Within the System's current Phase 3 clinical trial program, more than 145 subjects have received the ELAD System therapy in seven clinical trials, which the company believes shows a promising therapeutic profile. In 2014 Vital Therapies launched an IPO.
  </p><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 IPO.flsnp" />
  <p>
   In April 2014 Vital Therapies launched an IPO and raised nearly $55 million. It plans to use $19 million, $22 million, and $8 million of the net proceeds to fund costs expected to be incurred in connection with its VTI-208 Phase 3 clinical trial, VTI-210 Phase 3 clinical trial, and VTI-212 Phase 2 clinical trial, respectively, over the next two years.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Strategy.flsnp" />
  <p>
   The company's first strategic initiative is to complete the ELAD System's clinical development in acute liver failure and obtain regulatory approval for the System in Europe and the US. It plans to establish a targeted sales force focused on liver transplant and specialist intensive care centers and eventually explore commercial opportunities for the ELAD System in other international markets.
  </p>
 <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
